EMERYVILLE, Calif. (AP) — Adamas Pharmaceuticals Inc. (ADMS) on Thursday reported a loss of $27.6 million in its third quarter.

On a per-share basis, the Emeryville, California-based company said it had a loss of 99 cents.

The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 90 cents per share.

The drugmaker posted revenue of $13.9 million in the period, also missing Street forecasts. Five analysts surveyed by Zacks expected $14.4 million.

In the final minutes of trading on Thursday, the company's shares hit $4.70. A year ago, they were trading at $13.06.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ADMS at https://www.zacks.com/ap/ADMS

Automated Insights

Load comments